Mr. Golestani has over 30 years of experience in health, life sciences and technology. At Merck, he led the company’s global Information Technology organization, strategy, and execution worldwide, spanning all lines of business inclusive of Human Health and Animal Health BioPharma. He was responsible for Merck’s portfolio of services and solutions companies, as well as its global health innovation venture fund – each of which extensively leverages opportunities across the digital health ecosystem. Previously, Mr. Golestani was a principal with Oracle in charge of establishing and managing strategic client relationships from business development through consulting services and engagement delivery.
The appointment comes on the heels of other significant developments for Zapata this year, including collaborations with Google and IBM, an exclusive license agreement with Harvard’s Office of Technology Development, and an initial round of funding from prominent investors that include The Engine, the venture firm founded by MIT to invest in tough tech startups.
